C R Bard Inc (BCR) : Todd Asset Management added new position in C R Bard Inc during the most recent quarter end. The investment management firm now holds 67,926 shares of C R Bard Inc which is valued at $14,932,173 , the company said in a statement filed on Aug 1, 2016 with the SEC.C R Bard Inc makes up approximately 0.46% of Todd Asset Management’s portfolio.
Other Hedge Funds, Including , Aberdeen Asset Management Plcuk boosted its stake in BCR in the latest quarter, The investment management firm added 1,445 additional shares and now holds a total of 65,510 shares of C R Bard Inc which is valued at $14,401,063. C R Bard Inc makes up approx 0.05% of Aberdeen Asset Management Plcuk’s portfolio.Morgan Dempsey Capital Management reduced its stake in BCR by selling 160 shares or 8.1% in the most recent quarter. The Hedge Fund company now holds 1,816 shares of BCR which is valued at $406,294. C R Bard Inc makes up approx 0.13% of Morgan Dempsey Capital Management’s portfolio.Strs Ohio boosted its stake in BCR in the latest quarter, The investment management firm added 603 additional shares and now holds a total of 7,448 shares of C R Bard Inc which is valued at $1,665,745. C R Bard Inc makes up approx 0.01% of Strs Ohio’s portfolio.Pennsylvania Trust Co boosted its stake in BCR in the latest quarter, The investment management firm added 450 additional shares and now holds a total of 2,045 shares of C R Bard Inc which is valued at $475,360. C R Bard Inc makes up approx 0.04% of Pennsylvania Trust Co’s portfolio. Fox Run Management L.l.c. sold out all of its stake in BCR during the most recent quarter. The investment firm sold 2,700 shares of BCR which is valued $627,615.
C R Bard Inc opened for trading at $220.22 and hit $221.73 on the upside on Thursday, eventually ending the session at $221.42, with a gain of 0.72% or 1.59 points. The heightened volatility saw the trading volume jump to 3,97,077 shares. Company has a market cap of $16,264 M.
On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.
Many Wall Street Analysts have commented on C R Bard Inc. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .C R Bard Inc was Downgraded by BofA/Merrill to ” Neutral” on Jul 8, 2016.
C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.